2024-03-12 14:29:05 ET
Sanofi (SNY)
Leerink Partners Global Biopharma Conference
March 12, 2024 10:40 AM ET
Company Participants
Naimish Patel - Global Head of Development for Immunology and Inflammation
Shaju Backer - Global Head of Immunology Franchise
Conference Call Participants
Dave Risinger - Leerink Partners
Presentation
Dave Risinger
All right. Good morning, everyone. So my name is Dave Risinger, I cover Diversified Biopharmaceuticals for Leerink Partners, and it’s very much my pleasure to welcome you to the session with Sanofi, and I’m pleased that we’re able to be joined by the two key leaders of the Immunology Franchise of the company, so Shaju Backer, to my immediate left, is the Global Head of Immunology Franchise, Naimish Patel, is the Global Head of Development for Immunology and Inflammation, and so thank you both being with us today.
And it’s actually, great timing on the heels of AAD. And so I thought, maybe you could start with just some comments on the momentum for the company and quick takeaways from AAD.
Shaju Backer
Sure. So Naimish and I might talk about the overall and then hand over to you on the exciting and little amount data we present at the AAD. So it's the first time we have, showcased the whole pipeline at a conference like AAD, And we have, specific events we organize pre-conference or around satellite meetings. And the feedback has been phenomenal. The number of assets we have in play in the dermatology space for AAD, HSPN, and not only just the technology, the platforms we have with the Nanobody platform, et cetera....
Read the full article on Seeking Alpha
For further details see:
Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript)